



Post Authorisation Assessments

Eziflea Plus 134 mg/120.6 mg Spot-on Solution for Medium Dogs Vm 08749/5123

01 April 2026	Submission of a Ph. Eur. CEP for an active substance.
08 October 2025	Change in legal entity of MA holder from EU Pharmaceuticals Limited, 37 Geraldine Road, London, SW18 2NR, United Kingdom to Chanelle Pharmaceuticals Manufacturing Ltd, Loughrea, Co Galway, H62 FH90, Ireland.
04 May 2024	Substantial changes in the updated version of the ASMF or the active substance part of the dossier.
19 December 2023	Change in the name of a manufacturer of the finished product.
01 November 2023	Change in the limits of an active substance. Change in the specification parameters and/or limits of the finished product: - Change outside the approved specifications limits range.
03 March 2023	Change in distribution category from POM-V to AVM-GSL for 30 products.
05 July 2022	Minor changes to manufacturing process for the finished product. Change to the holding time of the bulk product.